Tiziana Life Sciences to Showcase Foralumab Progress at Jefferies Conference
Event summary
- Tiziana Life Sciences (Nasdaq: TLSA) will present at the Jefferies Global Healthcare Conference on June 4, 2026.
- CEO Ivor Elrifi and COO Keeren Shah will discuss recent clinical and corporate updates.
- Foralumab, its lead candidate, has shown improvement or stability in all 14 patients dosed in an Expanded Access Program for na-SPMS.
- Phase 2a trial for non-active secondary progressive multiple sclerosis is ongoing.
The big picture
Tiziana’s focus on intranasal foralumab reflects a broader industry shift toward alternative drug delivery methods for neuroinflammatory diseases. The company’s ability to differentiate itself hinges on proving efficacy in progressive multiple sclerosis, a space with limited treatment options. Success here could position it as a key player in immunomodulation therapies.
What we're watching
- Clinical Validation
- How the Phase 2a trial results will impact foralumab’s regulatory pathway and commercial potential.
- Investor Sentiment
- Whether the conference presentation can sustain or boost Tiziana’s market valuation amid biotech volatility.
- Pipeline Expansion
- The pace at which Tiziana can leverage its nasal immunotherapy platform for other indications.
Related topics